Xiuman Zhou

Discovery ofa Potent APOBEC3B Inhibitor to AugmentAntitumor Immunity and Reduce Inflammatory Toxicity

Abstract APOBEC3B (A3B), a key driver of cancer mutagenesis, has emerged as a promising therapeutic target to be ablated to enhance antitumor immunity while reducing intestinal inflammation. Starting from SMC247 (3, 5-diiodotyrosine), a kelp-derived natural product, we identified...